{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:26:41Z","timestamp":1787905601517,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The City of Dublin Skin and Cancer Hospital Charity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01438-7","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T11:35:40Z","timestamp":1748172940000},"page":"1901-1913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-3462","authenticated-orcid":false,"given":"Niamh","family":"Kearney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-3173","authenticated-orcid":false,"given":"Emily K.","family":"Pender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-3486","authenticated-orcid":false,"given":"Collette","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-5049","authenticated-orcid":false,"given":"Glen","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-6114","authenticated-orcid":false,"given":"Donal","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"4","key":"1438_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","volume":"44","author":"T Sairenji","year":"2017","unstructured":"Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673\u201392.","journal-title":"Prim Care"},{"key":"1438_CR2","unstructured":"UK CaC. Epidemiology summary: incidence and prevalence of IBD in the United Kingdom. 2022."},{"key":"1438_CR3","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238.","journal-title":"J Immunol Res"},{"key":"1438_CR4","first-page":"1","volume":"17","author":"SC Sarangi","year":"2022","unstructured":"Sarangi SC, Pattnaik SS, Sinha S, Govindaraj R. An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF-\u03b1, interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor. Expert Rev Gastroenterol Hepatol. 2022;17:1\u201325.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"1438_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jid.2016.11.040","volume":"137","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Jemec GBE, Kimball AB, Bachelez H, Gislason GH, Thyssen JP, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137(5):1060\u20134.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1438_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaad.2016.08.031","volume":"76","author":"IE Deckers","year":"2017","unstructured":"Deckers IE, Benhadou F, Koldijk MJ, Del Marmol V, Horv\u00e1th B, Boer J, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol. 2017;76(1):49\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjd.21704","volume":"187","author":"MC Schneeweiss","year":"2022","unstructured":"Schneeweiss MC, Kirchgesner J, Wyss R, Jin Y, York C, Merola JF, et al. Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: classification: epidemiology. Br J Dermatol. 2022;187(5):692\u2013703.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1438_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","volume":"79","author":"M Fauny","year":"2020","unstructured":"Fauny M, Moulin D, D\u2019Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1438_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"10378","key":"1438_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"key":"1438_CR11","unstructured":"UCB. Bimekizumab phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks. 2023."},{"key":"1438_CR12","unstructured":"Kimball AB. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3 randomized, double-blind, placebo controlled multicentre study. American Academy of Dermatology Annual Meeting 2023. 2023."},{"issue":"5","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","volume":"180","author":"JR Ingram","year":"2019","unstructured":"Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009\u201317.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1438_CR15","first-page":"77","volume":"39","author":"WGW Pathirana","year":"2018","unstructured":"Pathirana WGW, Chubb SP, Gillett MJ, Vasikaran SD. Faecal calprotectin. Clin Biochem Rev. 2018;39(3):77\u201390.","journal-title":"Clin Biochem Rev"},{"key":"1438_CR16","unstructured":"NICE. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. National Institute for Health and Care Excellence. 2013."},{"key":"1438_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068947","volume":"380","author":"M Deputy","year":"2023","unstructured":"Deputy M, Devanaboina R, Al Bakir I, Burns E, Faiz O. The role of faecal calprotectin in the diagnosis of inflammatory bowel disease. BMJ. 2023;380: e068947.","journal-title":"BMJ"},{"issue":"Suppl 3","key":"1438_CR18","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"},{"key":"1438_CR19","unstructured":"Poullis A. Introduction to faecal calprotectin for GPs. NICE. 2015."},{"issue":"4","key":"1438_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ueg2.12069","volume":"9","author":"F D'Amico","year":"2021","unstructured":"D\u2019Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United Eur Gastroenterol J. 2021;9(4):451\u201360.","journal-title":"United Eur Gastroenterol J"},{"key":"1438_CR21","doi-asserted-by":"crossref","unstructured":"Nielsen VW, J\u00f8rgensen AR, Yao Y, Ring HC, Attauabi M, Madsen GR, et al. Characteristics of patients with hidradenitis suppurativa and concomitant inflammatory bowel disease. Int J Dermatol. 2023.","DOI":"10.1111\/ijd.16628"},{"key":"1438_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1159\/000530434","volume":"239","author":"P R\u00e9ka","year":"2023","unstructured":"R\u00e9ka P, Janka EA, Solt\u00e9sz L, Szab\u00f3 IL, Kapit\u00e1ny A, Dajnoki Z, et al. Chronic inflammatory intestinal disorders in hidradenitis suppurativa. Dermatology. 2023;239:592.","journal-title":"Dermatology"},{"key":"1438_CR23","doi-asserted-by":"crossref","unstructured":"Jfri A, Charrow A. Risk factors associated with hidradenitis suppurativa comorbid with inflammatory bowel disease and clinical phenotypes: a pilot case-control study. Int J Dermatol. 2022.","DOI":"10.1111\/ijd.16311"},{"key":"1438_CR24","unstructured":"Baskerville R, Thompson M, Price CP, Heneghan C, Pl\u00fcddemann A. Point-of-care calprotectin tests. national institute for health research diagnostic evidence co-operative oxford. 2014."},{"issue":"6","key":"1438_CR25","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"15","key":"1438_CR26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.2015.13183","volume":"314","author":"ER Myers","year":"2015","unstructured":"Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314(15):1615\u201334.","journal-title":"JAMA"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01438-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:59:35Z","timestamp":1748685575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01438-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Niamh Kearney has received honoraria from AbbVie, Lilly, Janssen and UCB and has acted as a sub-investigator in clinical trials for AbbVie, MoonLake and UCB. Collette McCourt has received honoraria from AbbVie, Janssen, Lilly, UCB and Almirall and has acted as sub-investigator in clinical trials for AbbVie. Donal O\u2019Kane has received honoraria as a speaker and \/or advisory board member for Abbvie, Novartis, Lilly, UCB and Janssen. Brian Kirby has received research support from\/was a principal investigator (clinical trials) for AbbVie, Almirall, Janssen, Moonlake, Merck Sharpe Dolme, Novartis, Pfizer and UCB; been a consultant for AbbVie, Almirall, Celgene, Janssen, Merck Sharpe Dolme, Moonlake, Novartis, Pfizer and UCB; received honoraria from AbbVie, Almirall, Celgene, Janssen, Lilly, Moonlake, Novartis, Pfizer and UCB; and been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, Moonlake, Novartis, Pfizer and UCB. Emily Pender, Rosalind Hughes, Graham Turner, Graham Morrison, Glen Doherty and Juliette Sheridan have nothing to disclose. Niamh Kearney has changed affiliation after completion of the manuscript to Department of Dermatology, Our Lady of Lourdes Hospital, Drogheda, Louth, Ireland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved in Northern Ireland by the Preston-Northwest research ethics committee and Belfast Trust research office (IRAS ID 294497) and in Ireland by the St. Vincent\u2019s Healthcare Group Ethics and Medical Research Committee (RS21-040). This study was performed in accordance with the Helsinki Declaration of 1964. All patients provided written informed consent prior to their participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}